Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis

Figure 1 Survival according to CCR5-Δ32, SDF-1 3’A and MCP-1 (-2518) allele carriage. None of the studied polymorphisms had an influence on survival (at least one mutated allele carriers vs wild type homozygotes). CCR5-Δ32: Quartile time of survival = 112 mo vs 120 mo [RR = 1.02 (95% CI = 0.3-3.4), P = 0.3]; SDF-1 3’A: Quartile time of survival = 114 mo vs 149 mo [RR = 1.9 (95% CI = 0.8-4.4), P = 0.1]; MCP-1 (-2518): Quartile time of survival = 139 mo vs 115 mo [RR = 0.5 (95% CI = 0.1-1.5), P = 0.2].

Figure 2 HCC incidence according to CCR5-Δ32, SDF-1 3’A and MCP-1 (-2518) allele carriage. None of the studied polymorphisms had an influence on the risk of HCC occurrence (at least one mutated allele carriers vs wild type homozygotes). CCR5-Δ32: Quartile time to HCC occurrence = 72 mo vs 68 mo [RR = 0.5 (95% CI = 0.2-1.6), P = 0.3]; SDF-1 3’A: Quartile time to HCC occurrence = 72 mo vs 68 mo, [RR = 1.1 (95% CI = 0.6-2.0), P = 0.6]; MCP-1 (-2518): Quartile time to HCC occurrence = 67 mo vs 72 mo [RR = 1.1 (95% CI = 0.5-2.1), P = 0.8].